EVH dividend history

Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path.Proceeds from the transaction to be used to prepay senior term debt; Immediately accretive to Evolent's free cash flow by more than $7 million per year.Evolent reiterates outlook for Q3 2025 and full year 2025 for Revenue and Adjusted EBITDA, excluding the effect of the transaction.WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced that it has agreed to sell its value-based primary care business, Evolent Care Partners ("ECP"), to Privia Health Grou

Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON, June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M. John Johnson, Evolent's Chief Financial Officer, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thi